Results 41 to 50 of about 106,290 (280)

Dimethyl fumarate combined with cisplatin at subcytotoxic doses sensitizes cervical cancer toward ferroptosis and apoptosis through GSH restriction and p53 (re)activation

Molecular Oncology, EarlyView.
Dimethyl fumarate (DMF) reduces growth of HPV‐positive cervical cancer spheroids and induces ferroptosis in cervical cancer cells via blocking SLC7A11/Glutathione (GSH) axis. Combination of subcytotoxic doses of DMF and cisplatin (CDDP) further suppresses spheroid growth and drives cell death in 2D culture models.
Carolina Punziano, Giuseppina Minopoli, Simona Romano, Laura Marrone, Katia Aquilano, Maria Lina Tornesello, Raffaella Faraonio   +6 more
wiley   +1 more source

Oxaliplatin-related neuropathy in Indian patients – no difference between generic and original molecules

Indian Journal of Medical and Paediatric Oncology, 2016
Background: Oxaliplatin-induced neuropathy is a dose-limiting toxicity that significantly affects patients' quality of life. The aim of this study was to compare its occurrence between a generic versus the original molecule in Indian patients.
Bhawna Sirohi, Vikas Ostwal, Shaheenah Dawood, Gilberto Lopes, Sanjay Talole, Chaitali Nashikkar, Shailesh Shrikhande   +6 more
doaj   +1 more source

UCN-01 enhances cytotoxicity of irinotecan in colorectal cancer stem-like cells by impairing DNA damage response [PDF]

, 2016
Colorectal cancer (CRC) is one of the most common and lethal cancers worldwide. Despite recent progress, the prognosis of advanced stage CRC remains poor, mainly because of cancer recurrence and metastasis.
Biffoni, Mauro, BUCCARELLI, MARIACHIARA, Cappellari, Marianna, De Luca, Gabriele, Fanciulli, Maurizio, Goeman, Frauke, Melucci, Elisa, PILOZZI, Emanuela, Ricci Vitiani, Lucia, SIGNORE, MICHELE   +9 more
core   +1 more source

Interrogating the immune landscape of microsatellite stable RAS‐mutated colon cancer

Molecular Oncology, EarlyView.
COLOSSUS project RAS‐mutated MSS colon cancer study explored transcriptomics and immune cell density by immunohistochemistry (IHC), Immunoscore (IS), ISIC/TuLIS scores, mutation counts, and detected different prevalences but similar microenvironment composition across immune markers with clinical relevance for future immunotherapy combination ...
Rodrigo Dienstmann, Eduardo García‐Galea, Alice O'Farrell, Zak Kinsella, Maxime Meylan, Florent Petitprez, Ingrid Arijs, Tom Venken, Hari Ps, Adrian Lärkeryd, Ian Miller, Janick Selves, Nadja Meindl‐Beinker, Fiorella Ruiz‐Pace, Elena Élez, Raquel Comas‐Navarro, Frank Lincoln, Dirk Fey, Gift Nyamundanda, Aoife Nolan, Joern Lewin, Raquel Perez‐Lopez, Jonathan Briody, Kathleen Bennett, Walter Kolch, David Matallanas, Alexander Kel, Enrique Arenas, Joaquín Arribas, Bart Ghesquière, Josep Tabernero, Julie Meilleroux, Deborah McNamara, Ray McDermott, Marvin Lim, Mary O'Reilly, Brian Bird, Lisa Stack, Lucia Moloney, Patrick Morris, Keith Egan, Maciej Milewski, Lars Scheuer, Joachim Behringer, Georg Bolz, Ramon Salazar, Cristina Santos, Andrea Ruiz, Orla Casey, Verena Murphy, Matthias Ebert, Livio Trusolino, Diether Lambrechts, Anguraj Sadanandam, Catherine Sautès‐Fridman, Jochen Prehn, Paolo Nuciforo, Jacques Fieschi, Florence Monville, Darran O'Connor, Wolf Fridman, Annette Byrne   +61 more
wiley   +1 more source

Riluzole prevents oxaliplatin-induced cold allodynia via inhibition of overexpression of transient receptor potential melastatin 8 in rats

Journal of Pharmacological Sciences, 2018
Oxaliplatin causes acute cold hypersensitivity in most patients. We previously reported oxalate derived from oxaliplatin induced cold allodynia via overexpression of transient receptor potential melastatin 8 (TRPM8) in the dorsal root ganglion (DRG) in ...
Shota Yamamoto, Nobuaki Egashira, Makoto Tsuda, Satohiro Masuda   +3 more
doaj   +1 more source

Susceptibility of different mouse strains to oxaliplatin peripheral neurotoxicity: Phenotypic and genotypic insights. [PDF]

PLoS ONE, 2017
Peripheral neurotoxicity is one of the most distressing side effects of oxaliplatin therapy for cancer. Indeed, most patients that received oxaliplatin experience acute and/or chronic severe sensory peripheral neuropathy.
Paola Marmiroli, Beatrice Riva, Eleonora Pozzi, Elisa Ballarini, Dmitry Lim, Alessia Chiorazzi, Cristina Meregalli, Carla Distasi, Cynthia L Renn, Sara Semperboni, Lavinia Morosi, Federico A Ruffinatti, Massimo Zucchetti, Susan G Dorsey, Guido Cavaletti, Armando Genazzani, Valentina A Carozzi   +16 more
doaj   +1 more source

Amifostine protects from the peripheral sensory neuropathy induced by oxaliplatin in mice [PDF]

Brazilian Journal of Medical and Biological Research, 2020
Sensory neuropathy is a dose-limiting side effect of oxaliplatin-based cancer treatment. This study investigated the antinociceptive effect of amifostine and its potential neuroprotective mechanisms on the oxaliplatin-related peripheral sensory ...
A.F. Pereira, J.A. Lino, B.W.F. Alves, M.R.P. Lisboa, R.B. Pontes, C.A.V.G. Leite, R.B. Nogueira, R.C.P. Lima-Júnior, M.L. Vale   +8 more
doaj   +2 more sources

Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. [PDF]

, 2013
PurposePatients with advanced cholangiocarcinoma (CC) and gallbladder carcinoma (GC) have few therapeutic options for relapsed disease. methods: Given the overall poor prognosis in this population and the availability of novel targeted therapies, we ...
Falchook, Gerald S, Fu, Siqing, Hess, Kenneth R, Hong, David S, Janku, Filip, Javle, Milind, Kaseb, Ahmed O, Kurzrock, Razelle, Naing, Aung, Piha-Paul, Sarina, Subbiah, Ishwaria M, Subbiah, Vivek, Tsimberidou, Apostolia M, Wheler, Jennifer J, Wolff, Robert A   +14 more
core   +2 more sources

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Epidemiology and natural history of central venous access device use and infusion pump function in the NO16966 trial [PDF]

, 2014
Background: Central venous access devices in fluoropyrimidine therapy are associated with complications; however, reliable data are lacking regarding their natural history, associated complications and infusion pump performance in patients with ...
A Surov, AA Martoni, C Araújo, C Twelves, D Fagnani, D Haller, DC McGee, DZ Xiang, E Chu, E Chu, E McKenna, E Van Cutsem, EA Poplin, EB Lamont, F Ng, G Perrocheau, H-J Schmoll, I Kriegel, J Cassidy, J Cassidy, J Kawamura, J Shen-Gunther, L Cavanna, L Garrison, LB Saltz, M Gann Jr, M Karthaus, M Verso, M W Saif, MM Beckers, N Barbetakis, N Starling, P Debourdeau, R Biffi, S Lee, T Cartwright, T Conroy, The Meta-Analysis Group In Cancer, W Saber, W Scheithauer, W Sun, Y Inaba   +41 more
core   +2 more sources